1. Home
  2. PHVS vs MEG Comparison

PHVS vs MEG Comparison

Compare PHVS & MEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • MEG
  • Stock Information
  • Founded
  • PHVS 2015
  • MEG 2012
  • Country
  • PHVS Switzerland
  • MEG United States
  • Employees
  • PHVS N/A
  • MEG N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • MEG Professional Services
  • Sector
  • PHVS Health Care
  • MEG Consumer Discretionary
  • Exchange
  • PHVS Nasdaq
  • MEG Nasdaq
  • Market Cap
  • PHVS 980.9M
  • MEG 764.0M
  • IPO Year
  • PHVS 2021
  • MEG 2020
  • Fundamental
  • Price
  • PHVS $22.99
  • MEG $22.75
  • Analyst Decision
  • PHVS Buy
  • MEG Buy
  • Analyst Count
  • PHVS 6
  • MEG 5
  • Target Price
  • PHVS $37.17
  • MEG $31.80
  • AVG Volume (30 Days)
  • PHVS 59.1K
  • MEG 369.3K
  • Earning Date
  • PHVS 08-13-2025
  • MEG 08-05-2025
  • Dividend Yield
  • PHVS N/A
  • MEG N/A
  • EPS Growth
  • PHVS N/A
  • MEG N/A
  • EPS
  • PHVS N/A
  • MEG N/A
  • Revenue
  • PHVS N/A
  • MEG $718,904,000.00
  • Revenue This Year
  • PHVS N/A
  • MEG $10.49
  • Revenue Next Year
  • PHVS N/A
  • MEG $7.06
  • P/E Ratio
  • PHVS N/A
  • MEG N/A
  • Revenue Growth
  • PHVS N/A
  • MEG 10.92
  • 52 Week Low
  • PHVS $11.51
  • MEG $10.51
  • 52 Week High
  • PHVS $26.33
  • MEG $40.84
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 67.31
  • MEG 56.64
  • Support Level
  • PHVS $17.63
  • MEG $22.60
  • Resistance Level
  • PHVS $26.33
  • MEG $24.06
  • Average True Range (ATR)
  • PHVS 1.70
  • MEG 1.02
  • MACD
  • PHVS 0.65
  • MEG -0.08
  • Stochastic Oscillator
  • PHVS 65.24
  • MEG 63.20

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About MEG Montrose Environmental Group Inc.

Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.

Share on Social Networks: